Ionis has won an FDA green light for an RNA-based hereditary angioedema (HAE) treatment, Dawnzera, that can be self-administered by patients every four or eight weeks. The first-in-class drug targets ...

CSL has FDA approval for its new drug to prevent hereditary angioedema (HAE) attacks, Andembry, offering a new, first-in-class option for patients with the rare genetic disorder. Factor XIIa inhibitor ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...